BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 8772214)

  • 1. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
    Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
    Levine MN; Gent M; Hirsh J; Weitz J; Turpie AG; Powers P; Neemeh J; Willan A; Skingley P
    Arch Intern Med; 1996 Apr; 156(8):851-6. PubMed ID: 8774203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
    Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
    Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
    Camporese G; Bernardi E; Prandoni P; Noventa F; Verlato F; Simioni P; Ntita K; Salmistraro G; Frangos C; Rossi F; Cordova R; Franz F; Zucchetta P; Kontothanassis D; Andreozzi GM;
    Ann Intern Med; 2008 Jul; 149(2):73-82. PubMed ID: 18626046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
    Heit JA; Berkowitz SD; Bona R; Cabanas V; Corson JD; Elliott CG; Lyons R
    Thromb Haemost; 1997 Jan; 77(1):32-8. PubMed ID: 9031445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement.
    Gallay S; Waddell JP; Cardella P; Morton J
    Can J Surg; 1997 Apr; 40(2):119-23. PubMed ID: 9126125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
    Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
    Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
    Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.
    Arch Orthop Trauma Surg; 1992; 111(2):110-20. PubMed ID: 1314065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.